Feds offer up a new bonus plan for the R&D work they often pay for
As the nearly 1,000-page 21st Century Cures Act is implemented in phases, the full impact of the law is just beginning to be realized, and for one provision, the law has created a new program that rewards biopharmas for developing products that the government purchases and often pays to develop.
Background
Under section 3086 of the Cures Act, the FDA must establish a new priority review voucher program for material threat medical countermeasures — or MCMs — which are products that may be used in the event of a potential public health emergency, like an anthrax or ricin attack, or a naturally emerging disease like SARS or other natural disaster.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
